Results 121 to 130 of about 67,273 (233)

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source

Inhibition of larval growth of Ceratitis capitata Wied. by addition of antimetabolites to the larval diet. [PDF]

, 1986
A comparative study has been earried out in order to investigate the effects of cytarabine and ftorafur on the larval development and sex segregation of the Mediterranean fruit fly.Peer ...
Burgos, R., Muñiz, Mariano
core  

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Leukemia cutis as the first manifestation of acute myeloid leukemia

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Florian Winkler, Rosa Brand, Dino Mehic, Felix Tuchmann, Teresa Valero, Johanna Strobl   +5 more
wiley   +1 more source

Early Transplantation After Pretransplant Reduction of TP53‐Altered Clones and Prolonged Dose‐Adjusted Azacitidine Maintenance: A Three‐Case Series

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT TP53‐altered myeloid neoplasms are associated with an extremely high risk of relapse even after allogeneic hematopoietic cell transplantation (allo‐HCT), and the optimal pretransplant and posttransplant strategies remain undefined. We report the cases of three patients with TP53‐altered myeloid neoplasms who achieved durable complete remission
Fuyuki Yamagata, Kyoko Yoshihara, Yasuhito Nannya, Mami Samori, Saki Takahashi, Tomoko Kumamoto, Yoshiyuki Fujita, Nobuto Utsunomiya, Satoshi Yoshihara   +8 more
wiley   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Toxic Encephalopathy Developing After High-dose Cytarabine in a Child with Burkitt Lymphoma: A Successful Treatment Case

Journal of Pediatric Emergency and Intensive Care Medicine
Chemotherapy drugs used in the treatment of leukemia and lymphoma can occasionally cause side effects. We present here a rare case of neurotoxicity that occurred after high-dose cytarabine (HiDAC) administration.
Meliha Kübra Kütükçü Görgülü, Can Acıpayam, Tuğba Kandemir Gülmez, Serkan Kırık, Nursel Yurttutan   +4 more
doaj   +1 more source

Stromal cell effects on melanoma cell drug response [PDF]

, 2013
Thesis (M.A.)--Boston UniversityObjective: Melanoma is currently one of the deadliest forms of skin disease in the United States. However in the past decade there have been significant advances in treatment.
Della Penna, Greg
core   +1 more source

Development and validation of a nutrition risk screening for patients with childhood cancer in Brazil (NUTRICCAN)

Nutrition in Clinical Practice, Volume 41, Issue 3, Page 768-778, June 2026.
Abstract Background Diagnosing malnutrition in patients with pediatric cancer is challenging because tumor masses can interfere with anthropometric measurements. STRONGkids considers cancer a general risk factor, whereas Screening Tool for Childhood Cancer (SCAN) classifies patients as at risk or not, potentially missing those who need nutrition ...
Cristiane Ferreira Marçon, Carolina Araújo dos Santos, Fernanda Luisa Ceragioli Oliveira   +2 more
wiley   +1 more source